Raynaud Disease Clinical Trial
Official title:
Efficacy and Tolerability of Ginkgo Biloba Extract EGb 761® in Patients With Raynaud´s Phenomenon
The aim of the study is to investigate the efficacy and safety of EGb 761® in patients with the primary Raynaud phenomenon, with regards to the frequency, duration and severity of vasospastic attacks.
Despite more than 150 years of research into the pathophysiology of Raynaud´s phenomenon it
is still not understood sufficiently. Three mean mechanisms responsible for Raynaud´s
phenomenon are discussed and fall into the following three categories:
- neurological malfunction
- pathological blood vessel wall and blood cell interactions
- inflammatory and immunological responses Based on these concepts different classes of
drugs have been tested. Although some therapies have shown effects, prolongation of the
therapy is often difficult due to side-effects.
Considering a prevalence of 5-10% in the general population, there is still a place and
probably a need for the development of new treatment concepts. Ginkgo biloba has shown to
have anti-oxidative and anti-platelet activities. In a small placebo controlled trial in
patients with the Raynaud´s phenomenon promising results for the Ginkgo biloba extract were
shown. EGb 761® is known to be safe and well tolerated. Based on the above considerations,
EGb 761® may be an effective treatment for Raynaud´s phenomenon.
Aim: To determine the efficacy and safety of EGb 761® in patients with Raynaud´s phenomenon
on the frequency, duration, and severity of vasospastic attacks compared to placebo.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01926847 -
Digital Flow Enhancement in Raynaud's Phenomenon With an sGC (Soluble Guanylate Cyclase) Stimulator
|
Phase 2 | |
| Completed |
NCT03699436 -
Effectiveness of Electric Stimulation Therapy in Raynaud's Phenomenon
|
N/A | |
| Terminated |
NCT02374320 -
Exparel as a Nerve Block for Severe Hand Pain
|
Phase 2/Phase 3 | |
| Completed |
NCT00253331 -
Lab Study of MQX-503 in Treatment of Raynaud's
|
Phase 2/Phase 3 | |
| Recruiting |
NCT02183779 -
PORH and Response to Cold in Raynaud's Phenomenon.
|
N/A | |
| Active, not recruiting |
NCT00934427 -
Study of a Topical Formulation for the Treatment and Prevention of Raynaud's Phenomenon Symptoms
|
Phase 3 | |
| Completed |
NCT02506062 -
A Trial of Ischemic Preconditioning in Raynaud's Phenomenon (RP)
|
N/A | |
| Terminated |
NCT02642146 -
Treatment of Digital Ulcers in Korean Patients With Systemic Sclerosis: a Prospective Cohort Study
|
||
| Completed |
NCT01743612 -
Laser Speckle Contrast Imaging for Cutaneous Microvascular Dysfunction Detection in Systemic Sclerosis.
|
N/A | |
| Completed |
NCT03094910 -
Investigation of the Rewarming og the Fingers After Cooling and the Autonomic Nervous System in Raynaud's Phenomenon
|
N/A | |
| Recruiting |
NCT02298777 -
Metabolomic Analysis of Systemic Sclerosis
|
||
| Completed |
NCT00626665 -
Randomised Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma
|
Phase 3 | |
| Completed |
NCT00004786 -
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis
|
Phase 3 | |
| Withdrawn |
NCT04898036 -
Phototherapy For Treatment Of Raynaud's Phenomenon
|
N/A | |
| Completed |
NCT03027674 -
Topical 10 % Nifedipine Versus 5% Sildenafil in Secondary Raynaud
|
N/A | |
| Terminated |
NCT03869008 -
Potential Benefit for Non Invasive Vagus Nerve Stimulation Using GammaCore in the Treatment of Raynaud's Phenomena.
|
N/A |